215 First Street
99 articles with Seres Therapeutics
The two companies will focus on utilizing the microbiome, all the bacteria, viruses and fungi in the body, to improve cancer immunotherapy.
Collaboration focused on further elucidating the potential of microbiome therapeutics to augment immuno-oncology treatment for cancer
Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates
Seres Therapeutics, Inc reported fourth quarter and full year 2018 financial results and provided an operational update.
Seres Therapeutics, Inc. announced that it will present at each of the following upcoming healthcare conferences
Seres Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Operational Progress Conference Call and Webcast on March 6, 2019
Seres Therapeutics, Inc. announced that management will host a conference call and live audio webcast on March 6, 2019 at 8:30 a.m. ET to discuss fourth quarter and full year 2018 results and provide a general business update.
2/8/2019In this week's edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles.
Focusing resources on clinical readouts from late-stage microbiome programs for ulcerative colitis, C. difficile infection and planned immuno-oncology study
Eric Shaff, previously Chief Operating and Financial Officer, appointed President and Chief Executive Officer
Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
Recent FDA correspondence indicates this SER-287 Phase 2B study may support Biologics License Application (BLA)
Seres Therapeutics, Inc. today announced that it will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13th at 9:30 a.m. ET.
Kevin Horgan, M.D. an accomplished drug developer and immunology expert, hired as Chief Medical Officer
Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018
Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on November 8, 2018 at 8:30 a.m. ET to discuss third quarter 2018 results and provide a general business update.
Dr. Horgan, an immunology and oncology drug development expert, is well positioned to drive Seres microbiome clinical programs forward
Findings support SER-109 Phase 3 program as a potential new treatment option for C. difficile infection
National MS Society Commits $12 Million to 40 New Research Projects to Stop Multiple Sclerosis, Restore Function and End MS Forever
A cutting-edge treatment for fatigue, strategies to repair myelin, and MS risk factor candidates are among the new leads being explored
Seres Therapeutics Strengthens Board of Directors with Appointment of Meryl Zausner, Experienced Biopharmaceutical Financial Leader
Seres Therapeutics, Inc. today announced the appointment of Meryl Zausner, a seasoned biopharmaceutical executive, to its Board of Directors. Ms. Zausner brings decades of financial and operational leadership experience in the pharmaceutical industry.
Company preparing to initiate SER-287 Phase 2b study for ulcerative colitis
Seres Therapeutics to Host Second Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on August 2, 2018
Seres Therapeutics, Inc. announced that management will host a conference call and live audio webcast on August 2, 2018 at 8:30 a.m. ET to discuss second quarter 2018 financial results and provide a general business update.
A live audio webcast of each presentation will be available under the “Investors and Media” section of Seres’ website.
Preclinical data provide mechanistic insights related to the potency of microbiome therapeutics to augment immuno-oncology treatments; initiation of clinical study in metastatic melanoma planned for later this year